Sökning: "cytotoxic drug development"
Visar resultat 16 - 20 av 53 avhandlingar innehållade orden cytotoxic drug development.
16. Targeting ALK and WIP1 : neuroblastoma precision medicine under development
Sammanfattning : Neuroblastoma is the childhood solid tumor accountable for the largest number of deaths, calling for improved treatment. Some genetic alterations are considered crucial in driving initiation and progression of neuroblastoma. These are usually associated with poor prognosis and are viewed as potential therapeutic targets. LÄS MER
17. Optimizing Chemotherapy in Childhood Acute Myeloid Leukemia
Sammanfattning : Despite major advances in our understanding of the biology of childhood acute myeloid leukemia (AML) and the development of new cytotoxic drugs, the prognosis of long-term survival is still only 60-65 %.In the present research, we studied the pharmacokinetics of drugs used in the induction therapy of childhood AML and performed in vitro drug sensitivity testing of leukemic cells from children with AML. LÄS MER
18. Approaches to Treatment of Children with Advanced Neuroblastoma
Sammanfattning : Children with advanced neuroblastoma are at high risk for relapse of multidrug resistant disease, despite initial response to intensive multimodality treatment. Neuroblastomas have similarities with immature neuroblasts seen during embryonic development of the sympathetic nervous system (the origin of these tumors). LÄS MER
19. All-Photonic Control of Biorelevant Processes using Molecular Photoswitches and Caged Compounds
Sammanfattning : The development of light-controlled molecular tools for in situ regulation of biological activity holds great promise e.g. for resolving dynamic aspects of cellular signal transduction and to overcome inherent pharmaceutic limitations such as poor drug selectivity. LÄS MER
20. Novel human in vitro systems for studies of drug inducted hepatotoxicity
Sammanfattning : Drug-induced liver injury (DILI) is a major human health concern, estimated to account for about half of all cases of acute liver failure in the general population. DILI also represents a significant problem in drug discovery, being one of the most common reasons for regulatory actions, including boxed warnings, restricted marketing and withdrawals of marketed drugs. LÄS MER